Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer

被引：0
|
作者：
Valentine, Mark [1 ]
Perhanidis, Jessica [2 ]
Hawkes, Carol [2 ]
Thaker, Premal [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] GlaxoSmithKline, Waltham, MA USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
291
引用
收藏
页码：S158 / S158
页数：1
相关论文
共 50 条
  • [21] Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
    Horowitz, N. S.
    Penson, R. T.
    Campos, S. M.
    Lee, J.
    Kendall, D. L.
    Krasner, C. N.
    Berlin, S. T.
    Roche, M.
    Duska, L. R.
    Matulonis, U. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US
    Wu, Lei
    Zhong, Lixian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 187 - 195
  • [23] Real-Life Data of Niraparib Maintenance Treatment in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 10 - 11
  • [24] PARP Inhibitor Rechallenge Could be an Effective Strategy in Platinum-Sensitive Ovarian Cancer: A Retrospective Study
    Zhong, Lin
    Wang, Haixia
    Lei, Cuirong
    Wang, Ling
    Tang, Qin
    Huang, Yiqin
    He, Misi
    Zou, Dongling
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2024, 38 (03): : 2609 - 2619
  • [25] The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer
    Gubbi, Ajit
    Kendrick, James E.
    Finkler, Neil J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (10) : 1105 - 1113
  • [26] Platinum-sensitive ovarian cancer recurrence after PARP-inhibitor maintenance at first line: a real-world scenario
    Loverro, Matteo
    Marchetti, Claudia
    Capomacchia, Filippo Maria
    Caricato, Chiara
    Giannarelli, Diana
    Scambia, Giovanni
    Fagotti, Anna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A397 - A397
  • [27] MAINTENANCE OLAPARIB IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A COMPREHENSIVE CANCER CENTRE'S EXPERIENCE
    Moreira, I.
    Ferreira, M.
    Lopes, A. R.
    Savva-Bordalo, J.
    Abreu, M.
    Sousa, S.
    Pereira, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A241 - A241
  • [28] Efficacy of subsequent chemotherapy regimens in platinum-sensitive recurrent ovarian cancer following PARP inhibitor progression: a multicenter retrospective study
    Zhao, Yuxi
    Kang, Haili
    Zhao, Hongwei
    Wang, Li
    Duan, Wei
    Wu, Lingying
    Zuo, Jing
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A76 - A78
  • [29] Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis
    Kaneko, Masayuki
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (01) : 27 - 34
  • [30] Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer?
    Dottino, J. A.
    Moss, H. A.
    Lu, K. H.
    Secord, A. A.
    Havrilesky, L. J.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 11 - 12
12345